Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 17,274 shares at $19.98 ($345K) on 2024-11-11, disclosed to the SEC on 2024-11-13.
Scheduled sale ($345k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.98 | 8,637 | $173K | 50.0% |
| 2 | $19.98 | 8,637 | $173K | 50.0% |
| Total | $19.98 avg | 17,274 | $345K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |